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Previous reports have indicated that lactoferrin inhibits herpes simplex virus (HSV) infection during the very early phases of the viral
replicative cycle. In the present work we investigated the mechanism of the antiviral activity of lactoferrin in mutant glycosaminoglycan
(GAG)-deficient cells. Bovine lactoferrin (BLf) was a strong inhibitor of HSV-1 infection in cells expressing either heparan sulfate (HS) or
chondroitin sulfate (CS) or both, but was ineffective or less efficient in GAG-deficient cells or in cells treated with GAG-degrading enzymes.
In contrast to wild-type HSV-1, virus mutants devoid of glycoprotein C (gC) were significantly less inhibited by lactoferrin in GAG-
expressing cells, indicating that lactoferrin interfered with the binding of viral gC to cell surface HS and/or CS. Finally, we demonstrated that
lactoferrin bound directly to both HS and CS isolated from surfaces of the studied cells, as well as to commercial preparations of GAG
chains. The results support the hypothesis that the inhibition of HSV-1 infectivity by lactoferrin is dependent on its interaction with cell
surface GAG chains of HS and CS.
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Lactoferrin, an iron-binding glycoprotein composed of a
single 80-kDa polypeptide chain that is folded into two
homologous lobes (Moore et al., 1997), is a component of
many different exocrine fluids such as milk, tears, saliva,
bile, as well as bronchial, intestinal and vaginal secretions
(Vorland, 1999). Lactoferrin plays a part in the innate host
defense against pathogenic microorganisms and is a potent
inhibitor of several viruses including herpesviruses (Mar-
chetti and Superti, 2001; van der Strate et al., 2001; Vorland,
1999). The antimicrobial effects of lactoferrin may at least
partly be explained by its ability to interact with cell surface
molecules including glycosaminoglycans (GAGs) (van Ber-
kel et al., 1997).
GAG chains are ubiquitous components of cell surfaces
where most of them are covalently attached to core proteins to0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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specifically sulfated, disaccharide units of which two com-
mon classes are heparan sulfate (HS) and chondroitin sulfate
(CS). In the former, the disaccharide unit is composed of
uronic acid and glucosamine, whereas in the latter, the amino
residue is galactosamine. During synthesis, these sugar
residues are subjected to various modifications including
sulfation, and the distribution of negatively charged sulfate
groups along the chain is of prime importance for specific
recognition of GAGs by different proteins including the viral
attachment components. With regard to lactoferrin, GAG
molecules have been reported to modulate various biological
activities of this protein (Damiens et al., 1998), while lacto-
ferrin in turn was found to regulate the GAG/proteoglycan
activities in inflammation (Pejler, 1996) and during coagula-
tion (Wu et al., 1995).
Herpes simplex virus (HSV) type 1 (HSV-1) initiates
infection of cells by binding to cell surface GAG chains
(WuDunn and Spear, 1989), and this interaction is a
feature of both wild-type and laboratory strains (Terhune
et al., 1998; Trybala et al., 2002). Binding of viral
glycoproteins C (gC) and/or B (gB) to HS promotes virus
Fig. 1. Effect of HLf or BLf on HSV-1 KOS 321 and HSV-1 gC39 (A) and
HSV-1 wild-type 2762 and its gC-negative derivate 2762-5 (B) strain
infection in human embryonic fibroblasts. Lactoferrin and the virus were
simultaneously added to cells and left on the cell monolayers during 1 h
period of virus attachment to and infection of cells. The results are
expressed as percentages of the number of plaques developed in untreated
cultures. Data are means F SD of duplicate samples of a representative
experiment. Each experiment was repeated at least three times.
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while the interaction of glycoprotein D with specifically 3-
O-sulfated HS chains was shown to trigger the subsequent
entry step of this virus (Shukla et al., 1999). In addition,
HSV-1 and HSV-2, two related viruses that show prefer-
ential tropism for oral and genital tissue respectively, have
been reported to differ in their interaction with HS (Gerber
et al., 1995; Herold et al., 1996; Shukla et al., 1999;
Trybala et al., 2000).
After Hasegawa et al. (1994) demonstrated inhibitory
effects of lactoferrin against human cytomegalovirus and
HSV, many other viruses have also been reported to be
affected by this protein. In relation to the effect of lacto-
ferrin on other viruses, herpesviruses were shown to be
highly sensitive in various cell lines including those of
human origin (Andersen et al., 2003; Hasegawa et al., 1994;
Marchetti and Superti, 2001; Marchetti et al., 1996, 1998).
Moreover, Fujihara and Hayashi (1995) demonstrated a
protective effect of lactoferrin on murine herpetic keratitis.
With regard to the mechanism of its antiviral action, we
have previously demonstrated that the effect of lactoferrin
occurs during the very early phases of the viral replicative
cycle and seems unrelated to its iron content (Marchetti et
al., 1996, 1998). It has been postulated that lactoferrin may
compete with HSV for the attachment to cell surface HS
since GAG binding sites has been demonstrated to be
present on the N-terminal part of the protein (Ji and Mahley,
1994; Mann et al., 1994; Wu et al., 1995). In the present
work we have addressed this issue by testing the effect of
lactoferrin on HSV-1 infection of cells deficient or profi-
cient in expression of HS and CS (Banfield et al., 1995a;
Gruenheid et al., 1993; McCormick et al., 1998). Our study
demonstrates that a direct binding of lactoferrin to cell
surface GAG molecules constitute a hindrance for the gC-
mediated attachment of HSV-1 to HS and/or CS, and that
this feature may explain, at least in part, the anti-HSV
activity of the protein.Results
Antiviral activity of human and bovine lactoferrin in human
fibroblasts
The inhibitory potency of human lactoferrin (HLf) and
bovine lactoferrin (BLf) against different HSV-1 gC-posi-
tive and gC-negative strains was assayed in cultures of
human embryonic fibroblasts. Both HLf and BLf were
potent inhibitors of infection of cells by the gC-positive
wild-type 2762 strain and laboratory KOS 321 strain (Figs.
1A and B). The IC50 (concentrations inhibiting plaque
formation by 50%) values of HLf were 24 Ag/ml for the
2762 strain and 52.5 Ag/ml for KOS 321. The
corresponding values for BLf were 75 and 78 Ag/ml. Note
that at relatively low concentrations, HLf was more active
than BLf at inhibiting plaque formation by the wild-type2762 strain (Figs. 1A and B). Both proteins were signif-
icantly less active at inhibiting the gC-negative mutant
viruses gC39 and 2762-5 as compared to their parental
strains KOS 321 and 2762, respectively. The difference
between inhibition values found with KOS 321 and gC39
was more pronounced than that observed between 2762
and 2762-5.
Antiviral activity of human and bovine lactoferrin in
GAG-deficient mouse L cells
The results obtained in human cells suggested that gC is
important for an antiviral activity of lactoferrin. Since gC is
one of the major components that mediate virus attachment
to cells through interaction with HS chains, we sought to
investigate an involvement of GAG chains in the antiviral
activity of lactoferrin. To this end, we tested the effect of
HLf and BLf on HSV-1 infectivity in mutant HS-deficient
(gro2C) or HS- and CS-deficient (sog9) cells that were
selected from murine L fibroblasts based on their partial
resistance to HSV-1 infection. Gro2C cells were reported to
be 90% resistant to HSV-1 infection compared with L cells,
while sog9 cells showed approximately 95% resistance to
Fig. 2. Effect of BLf and HLf on HSV-1 KOS 321 infection in L, gro2C,
sog9 and sog9-EXT1 cells. (A) Dose-dependent effect of BLf on HSV-1
infection in L, gro2C, sog9 and sog9-EXT1 cells. BLf and the virus
inoculum were simultaneously added to and incubated with cells during 1 h
period of virus attachment to and infection of cells. Effect of BLf (B) or
HLf (C) on HSV-1 infection in L, gro2C, sog9 and sog9-EXT1 cells under
different experimental conditions. Lactoferrin (400 Ag/ml) was incubated
with cells either during adsorption and penetration step (1 h at 37 jC), or
throughout the infection (1 + 72 h at 37 jC), or during plaque formation
only (72 h at 37 jC). The results are expressed as percentages of the
number of plaques developed in untreated cultures. Data are means F SD
of duplicate samples of a representative experiment. Each experiment was
repeated at least three times.
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1995a). In addition sog9-EXT1, a cell line obtained by
transfection of sog9 cells with the EXT1 gene which
restored expression of HS but of no other GAG molecules
(McCormick et al., 1998), was used.
BLf and HSV-1 KOS 321 were simultaneously added to
cells and incubated for 1 h at 37 jC. Under these conditions,
BLf was inactive in sog9 cells even at the highest concen-
tration tested, while in L and gro2C cells, BLf reduced the
virus infection with IC50 values of 210 and 240 Ag/ml,
respectively. HSV-1 plaque formation in sog9-EXT1 cells
was strongly inhibited by BLf with approximately 80%
reduction noted at 250 Ag/ml (Fig. 2A). These results
indicated that the inhibitory effect of BLf was dependent
on the expression of HS and/or CS at the cell surface.
Results presented in Fig. 2B show the modulation of
HSV-1 infection by BLf (400 Ag/ml), investigated under
different experimental conditions. When BLf remained on
cells during the adsorption and penetration step (1 h at 37
jC) or when it was present throughout the infection (1 + 72
h at 37 jC), the inhibition of plaque formation ranged from
about 66% to 90% in L, gro2C and sog9-EXT1 cells. In
contrast, when BLf was added after the adsorption and
penetration step and incubated with cells for 72 h at 37
jC, no substantial inhibition in any of these cell lines was
observed. In GAG-deficient sog9 cells, BLf showed only a
weak effect on HSV infection. In these cells, the protein
marginally inhibited plaque formation when added during
the adsorption and penetration step, appeared to be com-
pletely ineffective when present throughout the infection,
and enhanced infection by 30% when added after the
adsorption and penetration step. Taken together, these results
suggest that BLf interfered with the virus attachment to and/
or entry into the cells through GAG interaction, but had little
effect on the later stages of infection. To further investigate
the effects of BLf on early events of HSV-1 infection, the
cells were incubated with BLf for 1 h at 4 jC before the virus
addition. The inhibitory effects were essentially similar to
those observed upon addition of BLf during the adsorption
and penetration step (data not shown), suggesting that the
viral receptor molecules at the cell surface were the site of
lactoferrin activity. However, the concentration of BLf
required to obtain a similar degree of inhibition was higher
at 4 jC than at 37 jC (2 mg/ml versus 400 Ag/ml). We have
no explanation for this phenomenon, but we can speculate
that BLf-GAG binding may, in addition to electrostatic
forces, rely on hydrophobic interactions that are known to
be less efficient at low temperature.
The results presented in Fig. 2C show the modulation of
HSV-1 infection by HLf at a concentration of 400 Ag/ml,
investigated under different experimental conditions, as
already described for BLf (see Fig. 2B). The most striking
difference between the two proteins was that HLf exhibited
a clear inhibition of HSV-1 infection not only in L, gro2C
and sog9-EXT1 cells, but also in sog9 cells. The observa-
tion that HLf showed antiviral activity during the initialphase of infection also in sog9 cells (Fig. 2C) suggested that
this protein, in contrast to BLf, could inhibit the virus
binding to cell surface molecules other than HS/CS.
Table 1
Effect of GAG-degrading enzymes on BLf activity against HSV-1 infection
Enzyme L cells Gro2C cells
% of BLf activity related to cells incubated without BLf
Mock treatment 100 100
Heparinase 70 85
Chondroitinase 130 15
Cells were treated with heparinase III (4 U/ml) or Chondroitinase ABC
(1 U/ml) or mock treated. The cells were then infected in the presence or
absence of BLf (400 Ag/ml).The activities of BLf were calculated according
to the following formula:
1 ðNo: of PFU with BLf and enzyme=No: of PFU with enzymeÞ
1 ðNo: of PFU with BLf=No: of PFUÞ  100
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The results presented in Fig. 2A suggested that GAGs are
important for antiviral activity of lactoferrin. Consequently,
BLf and HLf were tested for their ability to bind purified HS
and CS chains. HS chains isolated from L cells or CS chains
isolated from L or gro2C cells were mixed with lactoferrin
thereafter the GAG–lactoferrin complexes formed were
trapped on nitrocellulose filters. As shown in Fig. 3A,
BLf bound to GAG molecules isolated from L and gro2C
cells. At a concentration of 625 Ag/ml, BLf bound a higher
proportion of L cell-specific HS (90%) than CS from the
same source (37%). Interestingly, at the same concentration,
BLf bound efficiently to gro2C-specific CS (77%), a finding
suggesting that the CS chains expressed on HS-deficient
gro2C cells have been altered as compared with parental L
cells. The binding of HLf to purified HS or CS chains is
shown in Fig. 3B. HLf bound preferentially to HS and no
significant difference in the binding capability could be
noted between BLf and HLf at a concentration of 625 Ag/
ml. At a relatively low concentration (25 Ag/ml), BLf bound
45% more HS than HLf. These experiments clearly dem-
onstrated that BLf and HLf bound GAG molecules that are
M. Marchetti et al. / Vi408Fig. 3. Binding of BLf (A) or HLf (B) to HS and CS isolated from L and
gro2C cells. 35S-labeled HS/CS from L/gro2C cells were incubated with
lactoferrin for 2 h at room temperature. The amounts of bound
glycosaminoglycans were determined by the nitrocellulose membrane
filtration method. Values shown are averages of two individual determi-
nations from two separate experiments with two different glycosaminogly-
can preparations.primarily responsible for attachment of HSV-1 to cells, that
is, HS and to some lesser extent CS.
Effect of enzymatic treatment of cells on the antiviral
activity of bovine lactoferrin
Our data indicated that cell surface GAGs are important
for antiviral activity of lactoferrin (Figs. 2 and 3). To furtherFig. 4. Effect of CS-B and BLf on HSV-1 KOS 321 infection in L (A) and
gro2C (B) cells. Serial dilutions of CS-B were incubated with BLf (400 Ag/
ml) at room temperature for 15 min before infection of cells for 1 h at 37
jC. The results are expressed as percentages of the number of plaques
developed in untreated cultures. Data are means F SD of duplicate
samples of a representative experiment. Each experiment was repeated at
least three times.
Fig. 5. Effect of BLf against infection with HSV-1 KOS 321 and its gC
deletion mutant gC39 in L, gro2C, sog9 and sog9-EXT1 cells. BLf (400
Ag/ml) and the virus inoculum were simultaneously added to and incubated
with cells during 1 h period of virus attachment to and infection of cells.
The results are expressed as percentages of the number of plaques
developed in untreated cultures. Data are means F SD of duplicate
samples of a representative experiment. Each experiment was repeated at
least three times.
M. Marchetti et al. / Virology 318 (2004) 405–413 409challenge this interpretation, the L or gro2C cells were
treated with heparinase III and chondroitinase ABC before
the addition of the virus–lactoferrin mixture or the virus
alone (Table 1). As expected, treatment of L cells with
heparinase and treatment of gro2C cells with chondroitinase
reduced the number of viral plaques compared to mock-
treated controls, while chondroitinase-treated L cells and
heparinase-treated gro2C cells were readily infected by
HSV-1 (data not shown). The antiviral effect of BLf in
heparinase-treated cells was decreased as related to the
effect of BLf in untreated controls. In contrast, in chon-
droitinase-treated L cells, BLf inhibited HSV-1 infection
more efficiently than in mock-treated cells. Treatment of
gro2C cells with heparinase did not significantly affect BLf
antiviral activity while in chondroitinase-treated gro2C
cells, BLf was almost unable to inhibit plaque formation.
These results support our interpretation that the anti-HSV-1
effect of BLf is, at least partly, dependent on the blocking of
the virus binding to cell surface HS and/or CS.
Effect of chondroitin sulfate preparations on antiviral
activity of bovine lactoferrin
The inhibitory effect of CS-A, -B, -C or -D, alone or
combined with BLf, on HSV-1 infection in L, gro2C, sog9
and sog9-EXT1 cells, was then assayed. In a first series of
experiments, we have found that, of the CS preparations
used, CS-B from pig skin was the most active inhibitor of
HSV-1 infection (data not shown). Successively anti-HSV-
1 effect of CS-B, alone or combined and preincubated with
400 Ag/ml BLf before addition to L cells, was assayed (Fig.
4A). The modulation of BLf potency by CS-B was
dependent on the concentration of this compound used,
that is, at concentrations of < 50 Ag/ml CS-B enhanced,
whereas above this threshold, diminished the anti-HSV-1
potency of BLf. These tendencies were markedly less
pronounced in gro2C cells (Fig. 4B). Similarly to what
was observed by Banfield et al. (1995b), HSV-1 infection
of these HS-deficient cells was highly sensitive to inhibi-
tion with CS-B, and this feature might limit the discrim-
ination of modulation of anti-HSV potency of lactoferrin
by CS-B.
Effect of bovine lactoferrin on HSV-1 gC-null mutant
infection of GAG-deficient mouse L cells
In addition to examining the contribution of GAGs to
antiviral activity of lactoferrin (Figs. 2–4), we also inves-
tigated the involvement of viral gC in this process. Data
shown in Fig. 1 demonstrated that HSV-1 gC-negative
mutant viruses were significantly less sensitive to lactofer-
rin than parental strains. Given that, we assayed the activity
of BLf against the HSV-1 gC-null mutant gC39 in GAG-
deficient cells. BLf did not inhibit infection by gC39 in
any of the examined cell line (Fig. 5). On the contrary,
addition of lactoferrin during adsorption and penetrationstep promoted the formation of plaques by this mutant
virus, especially in gro2C, sog9 and sog9-EXT1 cells.
These findings indicate that BLf functions by blocking
the interaction of gC with cell surface HS and/or CS, and
that this substance can enhance infectivity of the gC-
negative variants.Discussion
We attempted to elucidate molecular mechanisms behind
the well-known anti-HSVactivity of lactoferrin (Fujihara and
Hayashi, 1995; Hasegawa et al., 1994; Marchetti et al., 1996,
1998). A proposal that lactoferrin blocks the virus adsorption
to target cells was previously formulated (Fujihara and Hay-
ashi, 1995; Marchetti et al., 1996). Here, by the use of cells
with selectively modified expression of GAG molecules, we
demonstrated that lactoferrin blocked HSV-1 infection by
binding to HS and/or CS on cell surfaces, thereby occupying
moieties functioning as initial receptors for this virus. More-
over, the antiviral activity of lactoferrin against HSV-1
depended on the presence of the attachment protein gC,
earlier shown to mediate virus binding to HS (Herold et al.,
1991) as well as to CS (Ma˚rdberg et al., 2002).
As a common feature of protein–GAG interactions, the
binding of lactoferrin to heparin, HS and CS have been
attributed to electrostatic interactions between the negatively
charged polysaccharides and clusters of basic amino acids
that compose the positively charged domain at the N-
terminal part of this protein (Mann et al., 1994; Shimazaki
et al., 1998; Wu et al., 1995). Similarly, the domain of HSV-1
gC that is responsible for HS as well as for CS binding
contains stretches of basic arginine residues enabling such
M. Marchetti et al. / Virology 318 (2004) 405–413410electrostatic interactions to occur (Ma˚rdberg et al., 2002;
Trybala et al., 1994). Therefore, a mechanism in which
lactoferrin blocks HSV-1 infection by competing out gC-
mediated binding to cell surface GAG molecules seems a
plausible explanation of its antiviral activity. This assump-
tion is supported both by the lack of antiviral activity of
lactoferrin on GAG-deficient cells, and its impaired effect on
gC-negative strains.
With regard to a comparison of HS and CS, respectively,
as targets for the anti-HSV-1 activity of lactoferrin, this issue
was investigated using BLf on mouse cells selectively
expressing HS or CS. It should be noted that in mouse cells,
HLf was a less effective antiviral compound (see below), and
bound less amount of HS and CS as compared to its bovine
homologue, why BLf was chosen for the comparison. BLf
was a potent inhibitor of HSV-1 infection in L and sog9-
EXT1 cells exposing HS on their surface. In the HS-deficient
gro2C cells, in which HSV-1 utilizes CS as a substitute
receptor for attachment (Banfield et al., 1995b), the function
of BLf was dependent on binding to this GAGmolecule since
chondroitinase treatment strongly abrogated the antiviral
activity of BLf. Taken together, these data strongly suggest
that BLf requires the presence of at least one of the twoGAGs
HS/CS on host cell for antiviral activity. Furthermore, as
judged by the results from selective enzymatic removal of HS
or CS in L cells, it is likely that BLf preferably acts by binding
to HS when both the GAGs are present (such as on L cells)
and utilizes CS as a second choice when this molecule is the
only alternative (i.e., as on gro2C cells).
Interestingly, heterogeneity of CS molecules present on L
cells and its derivate HS-deficient CS-expressing gro2C cells
was suggested by the present study. In particular, gro2C cell-
specific CS appeared to be a better ligand for lactoferrin than
L-cell-specific CS, suggestive of an adaptation of the syn-
thesis and/or modification of CS in the absence of HS in the
direction of higher affinity to a polycationic protein. Given
the considerable structural diversity that GAG molecules
from various sources may present (Shriver et al., 2002), the
versatility of BLf in binding well to HS as well as to some CS
populations might have bearings to the broad antimicrobial
scope of the protein. When we analyzed different CS prep-
arations, the CS-Bwas a strong blocker of HSV-1 infection in
gro2C cells as shown earlier (Banfield et al., 1995b). Pre-
incubation of CS-B with BLf showed an additive antiviral
effect of the two substances at lower concentrations, and an
abrogation of anti-HSV-1 activities at higher concentrations,
suggesting a direct physical interaction between BLf and CS-
B. It might be proposed that CS-B contains structural ele-
ments that can accommodate BLf as well as HSV-1 gC, but a
more detailed analysis was beyond the scope of this article.
Since the viral envelope protein gC plays a key role in the
adsorption of HSV-1 to cells by interacting with HS or CS,
comparing the inhibitory activity of BLf toward gC-positive
and gC-negative viruses could provide an independent chal-
lenge of the GAG dependency of the antiviral activity of
lactoferrin. The finding that the infection by gC-negativemutants was significantly less inhibited or even enhanced by
BLf (the latter probably by BLf-mediated bridging of viral
and cellular surfaces), suggested that the anti-HSV-1 activity
of the protein relied on interference with the binding of gC to
cell surface GAG molecules. Attachment of gC-negative
virions to cells was previously reported to be redundantly
mediated by viral glycoprotein gB (Herold et al., 1994) and
the two viral components gB and gC clearly differ in their
interaction with HS with regard to contribution of electro-
static forces (Trybala et al., 2000). It may therefore be
suggested that BLf affects viral adsorption by interacting
with structural features of the HS/CS molecules that are
involved in the binding to gC but not to other heparin-binding
HSV glycoproteins, such as gB.
Finally, since BLf and HLf have been shown to differ in
some structural features as well as in their binding to
heparin-like molecules (Mann et al., 1994; Moore et al.,
1997; Shimazaki et al., 1998; van Berkel et al., 1997; Wu et
al., 1995), we studied the anti-HSV-1 activity of HLf in
mutant L cells. In contrast to BLf, HLf inhibited viral
infection in gro2C and sog9 cells to a similar extent. This
finding, together with results showing that HLf bound
much less gro2C-specific CS than BLf, suggests that HLf
probably does not interact significantly with CS from
gro2C cells. Therefore, it can be postulated that the pres-
ence of HS/CS on the surface of mouse L cells has a
different relevance for the anti-HSV-1 activity of BLf as
compared to that of HLf. Other mechanisms, unrelated to
GAG binding, could have a preponderant role in HLf
inhibition of viral infection in a situation where HS is not
expressed on the surface of target cells. On the other hand,
it should be noted that commercial preparation of HLf
might contain variable amounts of molecules from which
two or three N-terminal arginine residues have been re-
moved by limited proteolysis (van Berkel et al., 1997), an
alteration that could decisively affect lactoferrin–GAG
interaction (Mann et al., 1994).
In conclusion, the results presented in this study could
contribute to the explanation of the mechanisms involved in
the anti-HSV activity of lactoferrin. Derivatives of this
natural glycoprotein, blocking the early stages of the virus
life cycle, might have therapeutic potential as an alternative
to conventional drugs when the appearance of resistant virus
strains or severe side effects compromise the effectiveness
of the therapy. Furthermore, the implication of cell surface
GAG binding as a mechanism for antiviral activity of
lactoferrin may have some bearings on the wide spectrum
of other viruses being inhibited by this protein.Materials and methods
Cells and viruses
Human embryonic fibroblasts were grown in Eagle’s
minimal essential medium (MEM) supplemented with 2
M. Marchetti et al. / VirologmM L-glutamine, 4% fetal calf serum (FCS) and 4% new-
born calf serum. Mouse L cells (clone 1D line of LMtk
murine fibroblasts) and the L-cell derivatives gro2C and
sog9 were grown in Dulbecco’s modified Eagle’s medium
(DMEM) with high glucose (4.5 g/l) supplemented with 10%
FCS in 5% CO2 atmosphere. The gro2C cell line lacks
expression of HS and the sog9 cell line lacks expression of
both HS and CS (Banfield et al., 1995a; Gruenheid et al.,
1993). Sog9-EXT1 cells were grown in DMEM high glucose
supplemented with 10% FCS and 700 Ag/ml G418 (Gibco
BRL) in 5% CO2 atmosphere. L, gro2C, sog9 and sog9-
EXT1 cells were a generous gift of Dr. Frank Tufaro,
University of British Columbia (Vancouver, Canada).
The HSV strains used were HSV-1 KOS 321, a plaque
purified isolate of wild-type strain KOS (Holland et al.,
1983), HSV-1 gC39, a gC-null derivative of KOS 321
(Holland et al., 1984), HSV-1 2762, a wild-type brain isolate
(Bergstro¨m et al., 1990) and HSV-1 2762-5 a spontaneously
occurring gC-negative variant of 2762. The latter virus
strain contained a premature stop codon at position W13
of the gC gene, and its gC-negative phenotype was con-
firmed by the lack of reactivity to three different anti-gC
MAbs (Bergstro¨m, unpublished).
Lactoferrin preparations and enzymes
Lactoferrin from bovine milk was supplied by Besnier
Bridel (Laval, France), whereas human milk lactoferrin was
purchased from Sigma Chemical Co. (St. Louis, MO). The
stocks were prepared in phosphate-buffered saline (PBS,
pH 7.2) at a concentration of 20 mg/ml and stored at  20
jC. CS-A, -B, -C, and -D were purchased from ICN
Biomedicals, Inc. (Irvine, CA). Heparinase III (heparitinase
I) and chondroitinase ABC were purchased from Sigma.
Concentrations of GAG lyases were expressed in Sigma
units/ml (1 Sigma unit corresponds to approximately
0.0017 IU).
Cytotoxicity
Confluent monolayers of L, gro2C, sog9 or sog9 EXT1
cells grown in 96-well tissue culture plates were washed and
exposed to serial 2-fold dilutions of CS-A, -B, -C, and -D or
GAG lyases for 1 h at 37 jC, then washed and incubated
with fresh medium. In the other experiments cells were
incubated with serial 2-fold dilutions of lactoferrin. After 3/
4 days at 37 jC, cell morphology was examined by light
microscopy and cell viability was determined by neutral red
uptake assay. Briefly, treated and untreated cells were
stained for 3 h at 37 jC with neutral red (50 Ag/ml),
thereafter cells were washed with PBS and fixed with 4%
formaldehyde, 10% CaCl2. The uptaken dye was extracted
by 1% acetic acid in 50% ethanol and the optical density
was measured at 550 nm in an ELISA-reader. None of the
drugs affected either morphology or viability of all cell lines
tested.Antiviral assay
Confluent monolayers of L, gro2C, sog9, sog9-EXT1
cells and human embryonic fibroblasts in six-well plates
were washed twice with culture medium and incubated for 1
h at 37 jC with 900, 1300, 80000, 5000 or 900 PFU/well,
respectively. These inocula were chosen because they pro-
duced comparable numbers of plaques in each well (100–
200). However, to exclude that the BLf inability of inhibit-
ing HSV-1 infection in sog9 cells was due to the high viral
inoculum, experiments were performed with serial 2-fold
dilutions of HSV-1 inoculum starting from 1000 PFU/well.
Lactoferrin was added in the following ways: before viral
adsorption (1 h at 4 jC), during adsorption and penetration
step (1 h at 37 jC), throughout the infection (1 + 72 h at 37
jC), or during plaque formation only (72 h at 37 jC). In
experiments with CS, various dilutions of the compound
were incubated with BLf at 400 Ag/ml at room temperature
for 15 min before infection. After viral adsorption and
penetration step (1 h at 37 jC), cells were washed two
times with medium, thereafter medium containing 1%
methylcellulose, 2% FCS and antibiotics were added. Three
days after infection, monolayers were stained with crystal
violet and the plaques were counted.
Enzymatic digestion of cells with GAG lyases
Confluent monolayers of 3-day-old L and gro2C cells in
six-well plates were washed twice with Hanks’ medium and
incubated with heparinase III or chondroitinase ABC for 1
h at 37 jC. The cells were washed twice with cold Hanks’
medium and 900 or 1300 PFU (for L cells or gro2C cells,
respectively) were added to each well. Virus adsorption was
performed for 1 h at 4 jC with or without BLf in the
medium.
Isolation of heparan and chondroitin sulfate chains
Subconfluent cell monolayers were grown for 48 h (L
cells) or 65 h (gro2C cells) in the presence of Na2
35SO4 (50
ACi/ml; specific activity 1325 Ci/mmol; NEN Life Science
Products, Boston, MA) in sulfate-free MEM supplemented
with 10% FCS and antibiotics. Cell-associated HS and CS
chains were purified by the method of Lyon et al. (1994).
For the isolation of HS and CS chains from L cells, the
recovered GAG chains, after dialysis, were digested with 2
Sigma unit/ml of chondroitinase ABC or 15 Sigma unit/ml
of heparinase I, respectively, for 4 h at 37 jC.
Binding of lactoferrin to heparan and chondroitin sulfate
Lactoferrin was serially 5-fold diluted in 0.2 ml PBS
supplemented with 0.05% bovine serum albumin. Each
dilution was mixed with approximately 5000 cpm of 35S-
labeled HS from L cells or 3500 cpm of 35S-labeled CS
from L or gro2C cells. Following incubation for 2 h at room
y 318 (2004) 405–413 411
M. Marchetti et al. / Virology 318 (2004) 405–413412temperature, the amounts of bound GAGs were determined
by the nitrocellulose membrane (Aka Filter AB) filtration
method (Maccarana and Lindahl, 1993).Acknowledgments
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